Breaking Down Hybio Pharmaceutical Co., Ltd. Financial Health: Key Insights for Investors

Curious whether Hybio Pharmaceutical Co., Ltd. (300199.SZ) is a growth story or a balance-sheet risk in disguise? In Q3 2025 the company posted revenue of 133.68 million CNY, contributing to a trailing twelve months (TTM) revenue of 898.10 million CNY and 2024 annual revenue of 590.20 million CNY, while profitability paints a mixed picture with a TTM net income of -67.50 million CNY (net profit margin -7.52%) despite a healthy operating margin of 32.34%; at the same time leverage and liquidity raise alarms - total debt stood near 1.85 billion CNY with a debt-to-equity ratio of 289.73%, cash shrinking by 252.87 million CNY in the latest quarter, a current ratio of 0.37 and a quick ratio of 0.16 - yet market investors price in optimism with a market cap around 16.59 billion CNY, P/S of 18.47 and EV/EBITDA of 71.81, while strategic partnerships, FDA/EMA/NMPA-certified production lines and an expanding peptide pipeline suggest material growth levers; read on for a line-by-line breakdown of revenue drivers, profitability metrics, solvency signals, valuation dynamics and the key risks that will shape investor decisions

Hybio Pharmaceutical Co., Ltd. (300199.SZ) - Revenue Analysis

• Q3 2025 revenue: 133.68 million CNY, up 11.86% sequentially.
• TTM (trailing twelve months) revenue: 898.10 million CNY, up 121.72% year-over-year.
• FY 2024 revenue: 590.20 million CNY, a 36.82% increase versus 2023.
• Revenue per employee: 867,726 CNY across 1,035 employees.
• Market capitalization: ~16.59 billion CNY; share price: 18.67 CNY (as of Dec 2, 2025).
• Price-to-sales (P/S) ratio: 18.47, indicating premium valuation relative to sales.

• Strong TTM growth (+121.72% YoY) suggests recent revenue bases or acquisitions materially increased topline; monitoring composition (organic vs. inorganic) is essential.
• Sequential Q3 2025 improvement (+11.86%) points to momentum in operations or product uptake in the latest quarter.
• Revenue per employee (867,726 CNY) signals operational leverage; compare with peers to assess productivity advantage or headcount-driven scaling.
• P/S of 18.47 and market cap of ~16.59 billion CNY imply the market is pricing significant future growth and margin expansion into the stock price.

Hybio Pharmaceutical Co., Ltd. (300199.SZ) Profitability Metrics

Key profitability indicators for Hybio Pharmaceutical Co., Ltd. (300199.SZ) reveal contrasting signals: strong operating efficiency alongside negative net profitability and returns to equity holders. The following breakdown uses the most recent trailing twelve months (TTM) figures.

• TTM Net Income: -67.50 million CNY - results in a net profit margin of -7.52%.
• Operating Margin: 32.34% - indicates efficient core operations and solid gross-to-operating conversion.
• Return on Equity (ROE): -10.67% - negative returns on shareholders' equity, reflecting losses relative to equity base.
• Return on Assets (ROA): 2.23% - modest asset utilization generating some positive returns on assets.
• Return on Invested Capital (ROIC): 2.70% - low but positive returns on capital invested in the business.
• Earnings Per Share (EPS): -0.08 CNY; Price-to-Earnings (P/E): n/a - negative EPS makes P/E not applicable.

For additional context on ownership, trading activity and investor interest, see: Exploring Hybio Pharmaceutical Co., Ltd. Investor Profile: Who's Buying and Why?

Hybio Pharmaceutical Co., Ltd. (300199.SZ) - Debt vs. Equity Structure

Key balance-sheet and leverage metrics for Hybio Pharmaceutical paint a picture of a company carrying substantial indebtedness relative to its equity base, with constrained short-term liquidity and limited near-term ability to service interest from operating income.

• Total debt-to-equity ratio: 289.73% - high leverage versus equity.
• Total debt (Sep 2024): 1.85 billion CNY; Cash reserves: 137.8 million CNY; Net debt ≈ 1.71 billion CNY.
• Current ratio: 0.37 - indicates potential difficulty covering current liabilities.
• Quick ratio: 0.16 - limited liquid assets relative to short-term obligations.
• Interest coverage ratio: 1.12 - minimal cushion to meet interest from operating income.
• Enterprise value / EBITDA: 71.81 - implies a high valuation relative to EBITDA.

For deeper context on ownership, trading patterns and investor composition, see: Exploring Hybio Pharmaceutical Co., Ltd. Investor Profile: Who's Buying and Why?

Hybio Pharmaceutical Co., Ltd. (300199.SZ) - Liquidity and Solvency

Key liquidity and solvency metrics for Hybio Pharmaceutical Co., Ltd. indicate a company generating operating cash while facing tight short-term liquidity and a leveraged balance sheet.

• Net change in cash (latest quarter): -252.87 million CNY - a material decrease in cash reserves.
• Operating cash flow (latest period): +164.7 million CNY - positive operational cash generation despite reported net losses.
• Capital expenditures (CAPEX): 116 million CNY - ongoing investment in manufacturing and R&D.
• Cash on hand: ~95 million CNY versus total debt ~1.5 billion CNY - indicates reliance on external financing.
• Current ratio: 0.37; Quick ratio: 0.16 - potential short-term liquidity challenges.
• Total assets: 3.17 billion CNY; Total liabilities: 1.52 billion CNY; Debt-to-equity ratio: 2.90 - elevated leverage level.

• Implications for investors: the positive operating cash flow suggests the core business can generate liquidity, but the steep quarterly cash decline, low cash buffer (~95M CNY) versus ~1.5B CNY of debt, and sub-1 current/quick ratios raise refinancing and working-capital risks.
• Areas to monitor: short-term debt maturities, any upcoming capital raises, covenant exposure, and whether CAPEX is translating into higher-margin sales that improve cash conversion.

Exploring Hybio Pharmaceutical Co., Ltd. Investor Profile: Who's Buying and Why?

Hybio Pharmaceutical Co., Ltd. (300199.SZ) - Valuation Analysis

• Market capitalization: 16.59 billion CNY
• Share price: 18.67 CNY
• Price-to-Sales (P/S): 18.47
• Price-to-Book (P/B): 24.96
• Enterprise Value / EBITDA (EV/EBITDA): 71.81
• Enterprise Value / Revenue (EV/Revenue): 20.52
• Forward P/E: n/a (negative earnings projections)

• High multiples reflect either significant growth expectations, valuable proprietary assets (e.g., biologics, IP), or speculative sentiment.
• Negative forward earnings indicate short-term profitability pressure - current valuation rests on longer-term recovery or pipeline success.
• EV/EBITDA of 71.81 and EV/Revenue of 20.52 place heavy weight on future margin improvement; sensitivity to execution risk is elevated.
• P/B near 25 suggests the market values intangible assets and future cash flows far above book equity - capital structure and asset quality should be reviewed.
• Relative to typical industry peers, P/S of 18.47 is unusually high; compare against specific biologics/rare-disease peers rather than broad pharma indices.

Hybio Pharmaceutical Co., Ltd. (300199.SZ) - Risk Factors

• Net loss: -173.7 million CNY despite 590.2 million CNY revenue - indicative of continued cash burn from R&D and pipeline development.
• Total debt-to-equity ratio: 289.73% - a high leverage level that increases solvency risk and sensitivity to interest rate or revenue shocks.
• Current ratio: 0.37 - suggests the company may struggle to cover short-term obligations with current assets.
• Quick ratio: 0.16 - limited liquid assets to meet imminent liabilities without relying on inventory or additional financing.
• Interest coverage ratio: 1.12 - operating income covers interest expense by a slim margin, leaving little buffer for declines in earnings.
• Enterprise value / EBITDA: 71.81 - a very elevated valuation relative to EBITDA, implying high market expectations or limited current earnings.

Hybio Pharmaceutical Co., Ltd. (300199.SZ) - Growth Opportunities

• Strategic cooperation with BrightGene Pharmaceutical to safeguard overseas supply chains for innovative drugs, with particular emphasis on oral peptide products.
• Partnership objective: support global industrialization of BrightGene's innovative drugs by leveraging Hybio's peptide API production base and downstream capabilities.
• Regulatory credentials: Hybio's production lines have passed FDA, EMA and NMPA certifications, smoothing access to international markets and contract manufacturing opportunities.
• Therapeutic coverage: peptide-based drugs spanning diabetes, digestive/metabolic systems and obstetrics & gynecology, enabling cross-market commercialization.
• Integrated upstream-to-downstream capability (API → finished preparations) positions Hybio to capture value across the peptide value chain and scale exports.

• Export acceleration: FDA/EMA/NMPA certifications remove technical/regulatory barriers, increasing addressable markets and contract-manufacturing revenue potential.
• Supply-chain resilience: cooperation with BrightGene reduces overseas supply risks and can secure long-term offtake for oral peptide APIs and finished products.
• Revenue mix uplift: moving from API-only to integrated API + preparations can improve margins and reduce client concentration risk.
• Market tailwinds: a high-growth global peptide market (single-digit to high single-digit CAGR) supports scalable topline expansion if Hybio converts partnerships into commercial volumes.
• Pipeline leverage: commercializing BrightGene's innovative candidates could enlarge Hybio's product roster and accelerate international market penetration.

• Execution of BrightGene collaboration milestones (capacity reservations, GMP transfer, commercial supply agreements).
• Order flow and export contracts post-FDA/EMA approvals - indicators of international traction.
• Mix shift from API to finished preparations and any disclosed margin improvement.
• New product launches in diabetes and metabolic indications and measurable uptake in target markets.